See more : Vitro Biopharma, Inc. (VTRO) Income Statement Analysis – Financial Results
Complete financial analysis of MedX Health Corp (MDXHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedX Health Corp, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Vantea SMART S.p.A. (VNT.MI) Income Statement Analysis – Financial Results
- H. Lundbeck A/S (HLBBF) Income Statement Analysis – Financial Results
- Shengshi Elevator International Holding Group Inc. (SSDT) Income Statement Analysis – Financial Results
- HANSHIN Engineering & Construction Co., Ltd. (004960.KS) Income Statement Analysis – Financial Results
- Advance United Holdings Inc. (AUHIF) Income Statement Analysis – Financial Results
MedX Health Corp (MDXHF)
About MedX Health Corp
MedX Health Corp, a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, and internationally. The company offers SIAscopy, a medical device technology used to scan skin for suspicious moles and lesions; phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market; and SIAMETRICS, SIMSYS, and MoleMate, which creates real-time images for physicians and dermatologists to evaluate various types of moles or lesions within seconds. It operates DermSecure telemedicine platform that enables the web-based operation of its SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients' mole and lesion images along with other relevant patient information can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 456.09K | 510.61K | 563.10K | 530.07K | 860.25K | 1.09M | 1.09M | 817.06K | 1.17M | 877.73K | 579.65K | 728.29K | 872.58K | 657.36K | 451.38K | 1.15M | 1.06M | 2.60M | 2.93M | 2.74M | 1.32M |
| Cost of Revenue | 270.46K | 270.66K | 273.67K | 261.96K | 380.43K | 398.24K | 478.75K | 379.23K | 509.79K | 390.72K | 269.80K | 299.58K | 381.84K | 244.47K | 689.00K | 315.08K | 371.52K | 571.82K | 656.17K | 503.11K | 211.66K |
| Gross Profit | 185.63K | 239.95K | 289.44K | 268.11K | 479.82K | 689.19K | 614.49K | 437.83K | 661.63K | 487.02K | 309.85K | 428.71K | 490.74K | 412.89K | -237.63K | 834.39K | 684.27K | 2.02M | 2.28M | 2.24M | 1.11M |
| Gross Profit Ratio | 40.70% | 46.99% | 51.40% | 50.58% | 55.78% | 63.38% | 56.21% | 53.59% | 56.48% | 55.49% | 53.45% | 58.87% | 56.24% | 62.81% | -52.65% | 72.59% | 64.81% | 77.98% | 77.62% | 81.65% | 83.97% |
| Research & Development | 586.08K | 681.80K | 995.36K | 431.16K | 535.46K | 880.77K | 182.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 121.79K | 286.50K | 138.75K | 16.80K | 22.41K | 105.18K | 164.58K |
| General & Administrative | 1.66M | 1.80M | 2.08M | 2.79M | 2.94M | 3.80M | 1.83M | 1.56M | 1.30M | 1.00M | 1.20M | 1.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 554.56K | 1.15M | 1.47M | 585.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.21M | 2.94M | 3.55M | 2.79M | 2.94M | 3.80M | 1.83M | 1.56M | 1.30M | 1.00M | 1.20M | 1.71M | 1.28M | 1.30M | 2.29M | 3.18M | 2.62M | 3.00M | 3.69M | 2.23M | 1.32M |
| Other Expenses | -2.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 185.63K | 4.11M | 4.85M | 3.30M | 3.61M | 4.77M | 2.11M | 1.66M | 1.34M | 1.04M | 1.23M | 1.75M | 1.34M | 1.41M | 2.32M | 3.52M | 2.80M | 3.41M | 4.03M | 2.56M | 2.04M |
| Cost & Expenses | 3.48M | 4.38M | 5.13M | 3.56M | 3.99M | 5.17M | 2.59M | 2.04M | 1.85M | 1.43M | 1.50M | 2.05M | 1.73M | 1.65M | 3.00M | 3.83M | 3.17M | 3.99M | 4.68M | 3.07M | 2.25M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.15M | 1.27M | 777.61K | 58.17K | 125.03K | 101.89K | 115.62K | 66.82K | 28.08K | 10.36K | 113.05K | 162.10K | 111.14K | 0.00 | 907.00 | 74.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 51.83K | 51.69K | 51.81K | 79.45K | 136.25K | 100.82K | 101.59K | 104.86K | 44.22K | 40.58K | 37.45K | 42.29K | 68.33K | 26.93K | 33.75K | 44.19K | 441.85K | 157.85K | 145.03K | 123.19K | 86.52K |
| EBITDA | -2.38M | -3.82M | -4.54M | -2.95M | -3.02M | -3.98M | -1.39M | -1.16M | -637.39K | -514.97K | -885.43K | -1.28M | -688.63K | -965.65K | -2.52M | -2.64M | -1.67M | -1.23M | -1.60M | -202.55K | -847.27K |
| EBITDA Ratio | -521.55% | -747.48% | -801.09% | -556.53% | -348.06% | -366.37% | -127.38% | -136.50% | -54.41% | -58.67% | -152.75% | -175.71% | -89.97% | -146.90% | -558.13% | -229.78% | -158.55% | -41.23% | -54.73% | -7.39% | -64.19% |
| Operating Income | -3.03M | -3.87M | -4.56M | -3.03M | -3.13M | -4.08M | -1.49M | -1.22M | -681.61K | -555.55K | -922.89K | -1.32M | -853.36K | -992.57K | -2.55M | -2.69M | -2.12M | -1.23M | -1.75M | -325.73K | -933.79K |
| Operating Income Ratio | -663.25% | -757.61% | -810.29% | -571.52% | -363.90% | -375.64% | -136.67% | -149.33% | -58.19% | -63.29% | -159.22% | -181.51% | -97.80% | -150.99% | -565.60% | -233.62% | -200.40% | -47.31% | -59.67% | -11.88% | -70.74% |
| Total Other Income/Expenses | -1.56M | -1.27M | -760.79K | -170.06K | -145.91K | -101.79K | -110.27K | -115.14K | 182.36K | 350.97K | -969.46K | 782.72K | -185.27K | 0.00 | 0.00 | 0.00 | 24.67K | -161.52K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -4.58M | -5.13M | -5.32M | -3.20M | -3.28M | -4.19M | -1.60M | -1.34M | -499.25K | -204.58K | -1.89M | -539.22K | -868.09K | 0.00 | 0.00 | 0.00 | -2.09M | -1.39M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1,004.31% | -1,005.41% | -945.40% | -603.60% | -380.86% | -385.00% | -146.76% | -163.43% | -42.62% | -23.31% | -326.47% | -74.04% | -99.48% | 0.00% | 0.00% | 0.00% | -198.07% | -53.53% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.27M | 777.61K | 58.17K | 125.03K | 101.89K | 115.62K | 66.82K | 28.08K | 10.36K | 113.05K | 162.10K | 0.00 | 0.00 | 6.01K | 81.32K | 38.46K | 169.01K | 18.60K | 74.92K | 509.05K |
| Net Income | -4.58M | -5.13M | -5.32M | -3.20M | -3.28M | -4.19M | -1.60M | -1.34M | -499.25K | -204.58K | -1.89M | -539.22K | -868.09K | -992.57K | -2.56M | -2.77M | -2.10M | -1.56M | -1.77M | -400.66K | -1.44M |
| Net Income Ratio | -1,004.31% | -1,005.41% | -945.40% | -603.60% | -380.86% | -385.00% | -146.76% | -163.43% | -42.62% | -23.31% | -326.47% | -74.04% | -99.48% | -150.99% | -566.94% | -240.69% | -198.53% | -60.04% | -60.31% | -14.61% | -109.31% |
| EPS | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 | 0.00 | -0.04 | -0.01 | -0.02 | -0.03 | -0.09 | -0.11 | -0.14 | -0.10 | -0.12 | -0.03 | -0.13 |
| EPS Diluted | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | -0.01 | 0.00 | -0.04 | -0.01 | -0.02 | -0.03 | -0.09 | -0.11 | -0.14 | -0.10 | -0.12 | -0.03 | -0.13 |
| Weighted Avg Shares Out | 196.71M | 183.74M | 180.18M | 166.56M | 140.19M | 130.35M | 103.75M | 83.63M | 70.71M | 67.40M | 42.76M | 36.51M | 34.98M | 30.27M | 27.02M | 24.10M | 15.06M | 15.04M | 14.63M | 12.12M | 10.80M |
| Weighted Avg Shares Out (Dil) | 196.71M | 183.74M | 180.18M | 166.56M | 140.19M | 130.35M | 103.75M | 83.63M | 70.71M | 67.40M | 42.76M | 36.51M | 34.98M | 30.27M | 27.02M | 24.10M | 15.06M | 15.04M | 14.63M | 12.12M | 10.80M |
MedX Health launches DermSecure screening services at Medicure clinic in Mississauga, Ontario
MedX Health Corp revealed that it is now offering its DermSecure screening services at the Medicure (TSX-V:MPH) clinic in Mississauga, Ontario - the first launch of its platform in a blended physician and pharmacy clinic setting in Canada. Under the...
MedX Health adds three new locations offering its flagship DermSecure Screening Platform in Ontario
MedX Health Corp, a leader in teledermatology, has revealed that its flagship DermSecure Screening Platform services are being offered in Empower's The Medi-Collective (TMC) locations across Ontario, Canada. "As we enter the New Year, we remain optimistic about the opportunity...
MedX Health Corp and London Medical Laboratory announce commercialization pilot of world-class teledermatology screening platform in the UK
MedX Health Corp. (TSX-V:MDX) has announced a memorandum of understanding with the London Medical Laboratory Ltd on a commercialization pilot and distribution agreement for MedX's leading-edge DermSecure Screening Platform in the UK. The medical device and software company which focuses on skin health...
MedX Health positioned for a strong 2022, new CEO says as the company reports 3Q results
MedX Health Corp, the medical device and software company focused on skin health, said it is well positioned for a “strong” 2022 with its new management team in place. New CEO Sylvain Desjeans described 2021 as “a year of transition...
MedX convenes medical advisory boards of leading dermatologists in Canada and US
MedX Health Corp said it recently convened medical advisory boards of leading dermatologists across Canada and the US to explore clinical application opportunities for its image capture technology SIAscopy and patient management system DermSecure. The company said summarized findings from...
MedX says its teledermatology screening platform to be distributed by Al Zahrawi in the United Arab Emirates
MedX Health Corp. (TSX-V:MDX) and Al Zahrawi Medical Supplies LLC have struck a Memorandum of Understanding (MoU) on a two-phase commercialization pilot and distribution agreement for MedX's leading-edge DermSecure Screening Platform at select United Arab Emirates (UAE) oncology and dermatology...
MedX Health announces inaugural clinical trial of leading-edge teledermatology screening platform in Turkey
MedX Health Corp has announced an inaugural clinical trial of its leading-edge DermSecure Screening Platform at three university hospitals across Turkey in early 2022. Through its recently announced distribution agreement with Makromed/Arhan Global AŞ, MedX's flagship DermSecure Screening Platform will...
MedX Health to bring its leading-edge DermSecure Screening Platform to Turkey
MedX Health Corp. (TSX-V:MDX) is bringing its leading-edge DermSecure Screening Platform to Turkey. The company said it has entered into a memorandum of understanding with Makromed/Arhan Global A.
MedX Health announces appointment of Lesley Bourget as chief financial officer
MedX Health Corp announced that seasoned pharmaceutical finance executive Lesley Bourget will be joining the company as its chief financial officer on November 8, 2021. The Mississauga, Ontario-based company shared that Bourget's appointment will further support MedX's global commercialization strategy,...
MedX Health and partner to run pilot program for its DermSecure Screening Platform in Italy
MedX Health Corp. and Vitamed Biomedical s.r.l.
Source: https://incomestatements.info
Category: Stock Reports